Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Revenue (2023 - 2025)

Historic Revenue for Immunocore Holdings (IMCR) over the last 5 years, with Q3 2025 value amounting to $103.7 million.

  • Immunocore Holdings' Revenue rose 2921.57% to $103.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $379.6 million, marking a year-over-year increase of 2810.48%. This contributed to the annual value of $310.2 million for FY2024, which is 2436.53% up from last year.
  • Per Immunocore Holdings' latest filing, its Revenue stood at $103.7 million for Q3 2025, which was up 2921.57% from $98.0 million recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Revenue ranged from a high of $103.7 million in Q3 2025 and a low of $8.0 million during Q3 2021
  • In the last 5 years, Immunocore Holdings' Revenue had a median value of $69.0 million in 2022 and averaged $61.9 million.
  • As far as peak fluctuations go, Immunocore Holdings' Revenue skyrocketed by 66211.66% in 2022, and later surged by 342.89% in 2023.
  • Quarter analysis of 5 years shows Immunocore Holdings' Revenue stood at $8.9 million in 2021, then skyrocketed by 662.12% to $67.8 million in 2022, then increased by 3.43% to $70.2 million in 2023, then increased by 19.8% to $84.1 million in 2024, then rose by 23.37% to $103.7 million in 2025.
  • Its Revenue was $103.7 million in Q3 2025, compared to $98.0 million in Q2 2025 and $93.9 million in Q1 2025.